Previous studies have demonstrated that the MET-overexpressing RCC PDX harbors activating BRAF (G466A and D594N) mutations and is sensitive to both MET (INC280, or capmatinib) and MEK (trametinib) inhibition. Here, MET is linked to renal cell carcinoma.